Apogee Therapeutics, Inc.
APGE
$82.93
-$1.67-1.97%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 11.94% | 14.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.04% | 9.51% | |||
| Operating Income | -6.04% | -9.51% | |||
| Income Before Tax | -6.79% | -6.72% | |||
| Income Tax Expenses | 27.42% | 1.64% | |||
| Earnings from Continuing Operations | -6.81% | -6.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.81% | -6.71% | |||
| EBIT | -6.04% | -9.51% | |||
| EBITDA | -6.07% | -9.56% | |||
| EPS Basic | -3.27% | 6.89% | |||
| Normalized Basic EPS | -3.25% | 6.89% | |||
| EPS Diluted | -3.27% | 6.89% | |||
| Normalized Diluted EPS | -3.25% | 6.89% | |||
| Average Basic Shares Outstanding | 3.43% | 14.61% | |||
| Average Diluted Shares Outstanding | 3.43% | 14.61% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||